Latest news
-
RDD 2026 in review
RDD 2026 once again gathered inhaled and nasal drug experts in Scottsdale, AZ, USA for 4 days of presentations, workshops, posters, and exhibitions focused on emerging technology, with more than 400 people participating. The conference… [Read more . . .]
-
Lupin partners with ERN for launch Luforbec beclometasone / formoterol MDI in Spain
Lupin Limited announced that it has partnered with Laboratorios ERN for the launch of Lupin’s Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Spain. Luforbec, a generic version of Chiesi’s… [Read more . . .]
-
MannKind initiates Phase 2 INFLO-2 trial of MNKD-201 nintedanib DPI in patients with IPF
MannKind Corporation announced the initiation of the Phase 2 INFLO-2 trial of its MNKD-201 nintedanib DPI in patients with idiopathic pulmonary fibrosis. The 12-week INFLO-2 study is expected to enroll approximately 210 IPF patients who… [Read more . . .]
-
SoftOx Solutions initiates Phase 1 SIS-02 trial of SIS hypochlorous acid inhalation solution
SoftOx Solutions announced the initiation of its Phase 1 SIS-02 study of SIS hypochlorous acid inhalation solution in healthy volunteers as part of a European Defense Fund-supported effort to develop the inhalation solution as a… [Read more . . .]
-
Scienture announces new US patent covering Rezenopy naloxone nasal spray
Scienture Holdings, which acquired US rights to Summit Biosciences’s Rezenopy naloxone nasal spray in March 2025, announced that the United States Patent and Trademark Office has granted Summit US Patent No. 12,622,903 B2 covering Rezenopy… [Read more . . .]
Other recent news
-
Nebu-Flow gets £2 million Scottish Enterprise grant for continued development of its nebulizer technology
-
FDA approves MannKind’s sBLA for pediatric use of Afrezza insulin DPI
-
Kvvit acquires rights to Merz’s Inbrija levodopa DPI in mainland China, Hong Kong, and Macao
-
Inhaled SSO developer Rage Bio rebrands as Atisama Therapeutics
-
FDA tentatively approves Lupin’s ANDA for generic of Yupelri revefenacin inhalation solution
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
